BioCryst Pharmaceuticals
BCRX
£8.17
Share price
-0.90%
Change (1 day)
59.47%
Change (1 year)
Categories
Earnings for BioCryst Pharmaceuticals (BCRX)
Earnings in 2025 (TTM): -£40.06 Million
According to BioCryst Pharmaceuticals 's latest financial reports the company's current earnings are £0.50 Billion. In 2024 the company made an earning of -£64.53 Million, an increase over its 2023 earnings that were of -£0.17 Billion. The earnings displayed on this page is the company's Pretax Income.
Earnings history for BioCryst Pharmaceuticals from 1994 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | -£40.06 Million | -37.93% |
| 2024 | -£64.53 Million | -61.56% |
| 2023 | -£0.17 Billion | -7.43% |
| 2022 | -£0.19 Billion | 34.42% |
| 2021 | -£0.14 Billion | -0.55% |
| 2020 | -£0.14 Billion | 67.88% |
| 2019 | -£80.81 Million | 7.55% |
| 2018 | -£75.14 Million | 53.92% |
| 2017 | -£48.82 Million | 19.29% |
| 2016 | -£40.93 Million | 28.19% |
| 2015 | -£31.93 Million | -4.8% |
| 2014 | -£33.54 Million | 50.09% |
| 2013 | -£22.35 Million | -23.29% |
| 2012 | -£29.13 Million | -26.19% |
| 2011 | -£39.47 Million | 54.78% |
| 2010 | -£25.5 Million | 150.1% |
| 2009 | -£10.2 Million | -49.43% |
| 2008 | -£20.16 Million | 14.07% |
| 2007 | -£17.68 Million | -49.31% |
| 2006 | -£34.87 Million | 72.87% |
| 2005 | -£20.17 Million | 22.08% |
| 2004 | -£16.52 Million | 75.3% |
| 2003 | -£9.43 Million | -25.36% |
| 2002 | -£12.63 Million | 225.05% |
| 2001 | -£3.89 Million | -56.6% |
| 2000 | -£8.96 Million | 50.63% |
| 1999 | -£5.95 Million | 38.05% |
| 1998 | -£4.31 Million | -52.46% |
| 1997 | -£9.06 Million | 58.44% |
| 1996 | -£5.72 Million | -14.44% |
| 1995 | -£6.68 Million | 28.57% |
| 1994 | -£5.2 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | -£1.37 Million | -96.41% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -£0.13 Billion | 220.80% | 🇺🇸 USA |
 NanoViricides NNVC | -£7.22 Million | -81.00% | 🇺🇸 USA |
 Novavax NVAX | £0.37 B | -1,096.85% | 🇺🇸 USA |
 Gilead Sciences GILD | £5.06 B | -13,434.77% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -£0.17 Billion | 324.39% | 🇺🇸 USA |
 GlaxoSmithKline GSK | £4.01 B | -10,672.29% | 🇬🇧 UK |
 Emergent BioSolutions
EBS | -£0.67 Million | -98.24% | 🇺🇸 USA |
 Cel-Sci
CVM | -£19.22 Million | -49.40% | 🇺🇸 USA |